Einride and Lorenz Bring Autonomous Fleet to Production Facility in Germany
quarter
View All ->
9M 2026: Novonesis delivered 7% organic sales growth, confirming full-year outlook
COPENHAGEN, Denmark – November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales growth and adjusted EBITDA margin of 37.9%. In addition, our 2026 outlook is confirmed at 7-8% organic sales growth with an adjusted EBITDA margin at the higher end of the 37-38% range. Ester Baiget, President & CEO: “With strong sales and profitability, we continue to demonstrate the strength and resilience of Novonesis’ diversified business. Our ability to combine lea
Suominen Corporation’s Interim Report for January 1–September 30, 2026: Continued performance improvement in the third quarter
Suominen Corporation’s Interim Report on November 5, 2026, at 9:00 a.m. (EET) Suominen Corporation’s Half-Year Financial Report for January 1–June 30, 2026: Continued performance improvement in the third quarter In this financial report, the figures shown in brackets refer to the comparison period last year if not otherwise stated. July–September 2026 in brief: Net sales increased by 1.3% and amounted to EUR 101.1 million (99.8) Comparable EBITDA was EUR 5.1 million (3.4) Cash flow from operatio
newsAL Sydbank delivers best quarterly performance and raises its expectations
Company Announcement No 62/2026 Peberlyk 4 6200 Aabenraa Denmark Tel +45 74 37 37 37 AL Sydbank A/S CVR No DK 12626509, Aabenraa al-sydbank.com 5 November 2026 Dear Sirs AL Sydbank delivers best quarterly performance and raises its expectations AL Sydbank continues the positive trend from the first two quarters of the year and delivers its best quarterly result so far in 2026. Earnings rose, costs fell and the return on tangible equity exceeded the Bank’s target in Q3. Also, the integration of t
results
View All ->9M 2026: Novonesis delivered 7% organic sales growth, confirming full-year outlook
COPENHAGEN, Denmark – November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales growth and adjusted EBITDA margin of 37.9%. In addition, our 2026 outlook is confirmed at 7-8% organic sales growth with an adjusted EBITDA margin at the higher end of the 37-38% range. Ester Baiget, President & CEO: “With strong sales and profitability, we continue to demonstrate the strength and resilience of Novonesis’ diversified business. Our ability to combine lea
Eesti Energia Group Unaudited Results for Q3 2026
Sales Revenues and Profitability Eesti Energia Group's sales revenue in Q3 2026 totalled EUR 389 million, a 38% increase year-on-year. Group EBITDA more than doubled to EUR 60 million (Q3 2025: EUR 28 million). The Group earned a net profit of EUR 1.6 million, compared with a net loss of EUR 66.0 million in Q3 2025, which included an impairment of shale oil production assets of EUR 39.0 million. For the first nine months of 2026, sales revenue increased by 12% to EUR 1,329 million, EBITDA increa
newsDEMIRE delivers Q3 2026 results in line with expectations and confirms full-year guidance
DEMIRE delivers Q3 2026 results in line with expectations and confirms full-year guidance Rental income falls to EUR 33.9 million (previous year: EUR 41.4 million) due to a reduced portfolio EBIT returns to positive territory at EUR 10.9 million (previous year: EUR -28.1 million) FFO I* falls to EUR 2.8 million (previous year: EUR 8.3 million) Guidance for 2026 confirmed: rental income between EUR 42.5 million and EUR 44.5 million; FFO I* between EUR 0.5 million and EUR 2.5 million Langen , 5 No
third
View All ->
Suominen Corporation’s Interim Report for January 1–September 30, 2026: Continued performance improvement in the third quarter
Suominen Corporation’s Interim Report on November 5, 2026, at 9:00 a.m. (EET) Suominen Corporation’s Half-Year Financial Report for January 1–June 30, 2026: Continued performance improvement in the third quarter In this financial report, the figures shown in brackets refer to the comparison period last year if not otherwise stated. July–September 2026 in brief: Net sales increased by 1.3% and amounted to EUR 101.1 million (99.8) Comparable EBITDA was EUR 5.1 million (3.4) Cash flow from operatio
ArcelorMittal reports third quarter 2026 results
Luxembourg, November 5, 2026 - ArcelorMittal (referred to as “ArcelorMittal” or the “Company” or the "Group") (MT (New York, Amsterdam, Paris, Luxembourg), MTS (Madrid)), the world’s leading integrated steel and mining company, today announced results 1 for the three-month and nine-month periods ended September 30, 2026. 3Q 2026 key highlights: Safety focus: Protecting employee health and safety is a core Company value. The multi-year safety transformation continues to progress, focused on embed
newsSyensqo third quarter 2026 results
Press release Communiqué de presse Syensqo third quarter 2026 results Year-on-year sales growth accelerates to 9%, led by 13% growth in Materials; Underlying EBITDA increases sequentially to €320 million with operating cash flow of €284 million; Improved full-year operating cash flow & capex outlook Brussels, November 5, 2026, 7.00 am CET Q3 2026 Highlights Net sales of €1.59 billion driven by 7% year-on-year volume growth, led by Materials, and higher overall pricing (+2%). Acceleration in Mate
reports
View All ->
IMCD reports EBITA of EUR 425 million (+8%) in the first nine months of 2026
Rotterdam, The Netherlands (5 November 2026) - IMCD N.V. ("IMCD" or "Company"), a leading global partner for the sales, distribution, and formulation of speciality chemicals and ingredients, today announces its first nine months 2026 results. HIGHLIGHTS Revenue at EUR 3,965 million (+10% on a constant currency basis) Gross profit at EUR 991 million (+9% on a constant currency basis) EBITA at EUR 425 million (+11% on a constant currency basis) Free cash flow up by 12% to EUR 317 million (first ni
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update Ongoing negotiations with different parties towards securing a partnership or financing for the development of varoglutamstat in kidney disease Agreement with partner Simcere Pharmaceutical Group Ltd. to regain development and commercial rights for lead asset varoglutamstat in Greater China, consolidating global rights and supporting Vivoryon’s strategic focus on kidney disease New analysis performed by Luc
newsQ3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Q3 2026 Update: Tecan reports acceleration of sales growth in Q3 and raises full-year 2026 outlook Männedorf, Switzerland, November 5, 2026 – The Tecan Group (SIX Swiss Exchange: TECN) today provided an update on its performance for the third quarter of 2026, reporting an acceleration of sales growth to 6.9% in local currencies. Order entry grew by 3.1% in local currencies, despite a high comparison base from
financial
View All ->9M 2026: Novonesis delivered 7% organic sales growth, confirming full-year outlook
COPENHAGEN, Denmark – November 5, 2026. Novonesis delivered strong Q3 sales leading to 9M financial results at 7% organic sales growth and adjusted EBITDA margin of 37.9%. In addition, our 2026 outlook is confirmed at 7-8% organic sales growth with an adjusted EBITDA margin at the higher end of the 37-38% range. Ester Baiget, President & CEO: “With strong sales and profitability, we continue to demonstrate the strength and resilience of Novonesis’ diversified business. Our ability to combine lea
EfTEN United Property Fund unaudited financial results for 3rd quarter and 9 months of 2026
In the third quarter of 2026, EfTEN United Property Fund earned a net profit of 68 thousand euros (Q3 2025: 426 thousand euros). The decrease in profit is mainly related to the fund's investment in the development company Invego Uus-Järveküla OÜ, where the majority of the sales of completed terraced houses, and the resulting profit, fell in the previous year. Despite the decrease in profit, EfTEN United Property Fund received record income from its investments, which enabled the fund to make the
newsVivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update
Vivoryon Therapeutics N.V. Reports Q3 2026 Financial Results and Provides Business Update Ongoing negotiations with different parties towards securing a partnership or financing for the development of varoglutamstat in kidney disease Agreement with partner Simcere Pharmaceutical Group Ltd. to regain development and commercial rights for lead asset varoglutamstat in Greater China, consolidating global rights and supporting Vivoryon’s strategic focus on kidney disease New analysis performed by Luc
Magazine Focus
The New Growth Playbook: Building Businesses for Sustainable Expansion
Growth is being redefined. Expanding revenue remains important, but businesses are placing greater emphasis on profitability, cash discipline, operational efficiency, customer retention and resilience. This edition explores the changing growth playbook and the foundations required for sustainable expansion. From technology and process design to capital allocation and market reach, it examines how businesses can pursue ambition without allowing complexity, costs or uncontrolled expansion to weaken the enterprise.
For years, growth was often discussed primarily in terms of size, speed and market share. The conversation is becoming more balanced. Strong businesses also need healthy economics, efficient operations and the ability to withstand uncertainty. This edition looks at growth through that wider lens and considers how organizations can expand with greater discipline, clarity and long-term purpose in practice.
The day in focus. Delivered to your inbox.
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.